Next-Generation Sequencing Liquid Biopsy-Guided Osimertinib Rechallenge in EGFR-Mutated Advanced Non-Small-Cell Lung Cancer Patients

被引：0
|
作者：
Vered Fuchs
Waleed Kian
Rachel Lichtenberg
Jonah M. Cooper
Areen A. Remilah
Daniel Levin
Nir Peled
Laila C. Roisman
机构：
[1] Ben-Gurion University of the Negev,Goldman Medical School, Faculty of Health Sciences
[2] Shaare Zedek Medical Center,The Oncology Institute
[3] Ben-Gurion University of the Negev,Medical School for International Health
[4] The Institute of Nuclear Medicine and Molecular Imaging,undefined
来源：
Clinical Drug Investigation | 2022年 / 42卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：185 / 192
页数：7
相关论文
共 50 条
  • [21] Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance
    Fu, Kai
    Xie, Fachao
    Wang, Fang
    Fu, Liwu
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2022, 15 (01)
  • [22] Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance
    Kai Fu
    Fachao Xie
    Fang Wang
    Liwu Fu
    Journal of Hematology & Oncology, 15
  • [23] Osimertinib in first-line treatment of advanced EGFR-mutated non-small-cell lung cancer: a cost-effectiveness analysis
    Aguilar-Serra, Javier
    Gimeno-Ballester, Vicente
    Pastor-Clerigues, Alfonso
    Milara, Javier
    Marti-Bonmati, Ezequiel
    Trigo-Vicente, Cristina
    Alos-Alminana, Manuel
    Cortijo, Julio
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2019, 8 (11) : 853 - 863
  • [24] Mutation Profile of Resected EGFR-Mutated Lung Adenocarcinoma by Next-Generation Sequencing
    Zhao, Ze-Rui
    Lin, Yao-Bin
    Ng, Calvin S. H.
    Zhang, Rong
    Wu, Xue
    Ou, Qiuxiang
    Chen, Wendan
    Zhou, Wen-Jie
    Lin, Yong-Bin
    Su, Xiao-Dong
    Shao, Yang W.
    Long, Hao
    ONCOLOGIST, 2019, 24 (10): : 1368 - 1374
  • [25] Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer
    Uchibori, Ken
    Inase, Naohiko
    Araki, Mitsugu
    Kamada, Mayumi
    Sato, Shigeo
    Okuno, Yasushi
    Fujita, Naoya
    Katayama, Ryohei
    NATURE COMMUNICATIONS, 2017, 8
  • [26] Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer
    Ken Uchibori
    Naohiko Inase
    Mitsugu Araki
    Mayumi Kamada
    Shigeo Sato
    Yasushi Okuno
    Naoya Fujita
    Ryohei Katayama
    Nature Communications, 8
  • [27] Representativeness of Phase III Trial for Osimertinib in Pretreated Advanced EGFR-Mutated Non-small-cell Lung Cancer Patients and Treatment Outcomes in Clinical Practice
    Lin, Lishi
    Smit, Egbert F.
    de Langen, Adrianus J.
    van Balen, Dorieke E. M.
    Beijnen, Jos H.
    Huitema, Alwin D. R.
    TARGETED ONCOLOGY, 2022, 17 (01) : 53 - 59
  • [28] Patient-reported outcomes from FLAURA: Osimertinib versus erlotinib or gefitinib in patients with EGFR-mutated advanced non-small-cell lung cancer
    Leighl, Natasha B.
    Karaseva, Nina
    Nakagawa, Kazuhiko
    Cho, Byoung-Chul
    Gray, Jhanelle E.
    Hovey, Tina
    Walding, Andrew
    Ryden, Anna
    Novello, Silvia
    EUROPEAN JOURNAL OF CANCER, 2020, 125 : 49 - 57
  • [29] Representativeness of Phase III Trial for Osimertinib in Pretreated Advanced EGFR-Mutated Non-small-cell Lung Cancer Patients and Treatment Outcomes in Clinical Practice
    Lishi Lin
    Egbert F. Smit
    Adrianus J. de Langen
    Dorieke E. M. van Balen
    Jos H. Beijnen
    Alwin D. R. Huitema
    Targeted Oncology, 2022, 17 : 53 - 59
  • [30] Pan-Tumor Analytical Validation and Osimertinib Clinical Validation in EGFR Mutant Non-Small-Cell Lung Cancer, Supporting the First Next-Generation Sequencing Liquid Biopsy in Vitro Diagnostic
    Gray, Jhanelle E.
    Han, Ji-Youn
    Telaranta-Keerie, Aino
    Huang, Xiangning
    Kohlmann, Alexander
    Hodge, Rachel
    Rukazenkov, Yuri
    Chmielecki, Juliann
    Espenschied, Carin R.
    Lefterova, Martina
    Wu, Yi-Long
    Ramalingam, Suresh S.
    Barrett, J. Carl
    Odegaard, Justin I.
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2024, 26 (01): : 73 - 84
12345